VKTX Viking Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: VKTX

Price (delayed)

$75.76

Market cap

$8.35B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.93

Enterprise value

$8.16B

Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel, orally available, first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders. Viking's research and ...

Highlights
VKTX's equity has surged by 168% since the previous quarter
The company's quick ratio has surged by 55% QoQ
The EPS has declined by 2.2% since the previous quarter but it rose by 2.1% year-on-year
The net income fell by 30% YoY and by 9% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.vikingtherapeutics.com
Peers: GERN CYTK VBIV GALT

Key stats

What are the main financial stats of VKTX
Market
Shares outstanding
110.27M
Market cap
$8.35B
Enterprise value
$8.16B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
8.15
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$93.72M
EBITDA
-$93.43M
Free cash flow
-$54.87M
Per share
EPS
-$0.93
Free cash flow per share
-$0.53
Book value per share
$9.29
Revenue per share
$0
TBVPS
$9.35
Balance sheet
Total assets
$967.52M
Total liabilities
$33.63M
Debt
$1.18M
Equity
$933.89M
Working capital
$933.56M
Liquidity
Debt to equity
0
Current ratio
29.48
Quick ratio
29.38
Net debt/EBITDA
2.08
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-17.7%
Return on equity
-18.4%
Return on invested capital
-22.2%
Return on capital employed
-10%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

VKTX stock price

How has the Viking Therapeutics stock price performed over time
Intraday
-0.88%
1 week
10.02%
1 month
-2.06%
1 year
260.76%
YTD
307.09%
QTD
-7.61%

Financial performance

How have Viking Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$114.36M
Net income
-$93.72M
Gross margin
N/A
Net margin
N/A
Viking Therapeutics's operating income has plunged by 53% YoY and by 13% from the previous quarter
The net income fell by 30% YoY and by 9% QoQ

Growth

What is Viking Therapeutics's growth rate over time

Valuation

What is Viking Therapeutics stock price valuation
P/E
N/A
P/B
8.15
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has declined by 2.2% since the previous quarter but it rose by 2.1% year-on-year
The P/B is 172% more than the 5-year quarterly average of 3.0 and 54% more than the last 4 quarters average of 5.3
VKTX's equity has surged by 168% since the previous quarter

Efficiency

How efficient is Viking Therapeutics business performance
Viking Therapeutics's ROE has soared by 62% YoY and by 34% from the previous quarter
The ROIC has soared by 61% year-on-year and by 31% since the previous quarter
VKTX's ROA has soared by 59% year-on-year and by 33% since the previous quarter

Dividends

What is VKTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VKTX.

Financial health

How did Viking Therapeutics financials performed over time
The total assets has soared by 163% from the previous quarter
VKTX's total liabilities has soared by 100% YoY and by 68% from the previous quarter
Viking Therapeutics's debt is 100% lower than its equity
VKTX's equity has surged by 168% since the previous quarter
The debt to equity has plunged by 100% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.